中文摘要：

目的：比较富马酸奎硫平与利培酮对儿童青少年早发性精神分裂症的临床疗效、安全性和耐受性。方法：对61例发病年龄为10～18岁符合中国精神障碍分类与诊断标准第3版精神分裂症的诊断标准患者,采用富马酸奎硫平（31例）或利培酮治疗（30例）,以临床疗效总评量表（CGI-S）、简明精神病评定量表（BPRS）评估有效性,采用副反应量表（TESS）和一些重要生理指标包括血压、体重等评估安全性和耐受性,观察期限为4周。结果：富马酸奎硫平每日平均治疗剂量为835 mg±281 mg,平均加药时间为8.35天±5.89天。利培酮每日平均治疗剂量为5.83 mg±1.13 mg,平均加药时间为10.9天±3.82天。富马酸奎硫平与利培酮均对儿童青少年精神分裂症有确切疗效（P〈0.01）,应用两种药物治疗4周后BPRS减分率无统计学差异（P=0.876）;但富马酸奎硫平的锥体外系副反应明显少于利培酮（χ^2=4.510,P=0.034）。结论：本研究提示两种药物对治疗儿童青少年精神分裂症均有确切疗效,其中富马酸奎硫平的锥体外系副反应更少。

英文摘要：

Objective：To compare the efficacy,tolerability and security of quetiapine and risperidone in the treatment of early schizophrenia.Methods：Sixty one inpatients were treated with quetiapine or risperidone diagnosed as schizophrenia from CCMD-3 criteria.The efficacy and tolerability were assessed by using the Brief Psychiatric Rating Scale（BPRS）,Clinical Global Impression（CGI）,the Treatment Emergent Symptom Scale（TESS）,and index of physiological changes before and after treatment including blood pressure,heart rate and body weight were also assessed.The observation period was 4 weeks.Results：The mean daily doses of quetiapine and risperidone were 835 mg±281 mg and 5.83 mg±1.13 mg,respectively.The mean time of increase of dosage of quetiapine and risperidone were 8.35 days±5.89 days and 10.9 days ±3.82 days,respectively.Both treatments were effective in the treatment of early schizophrenia（P〈0.01）.Decrease rate in CGI scores after 4-week treatment had no significantly difference comparing the two groups（P=0.876）.However,the extrapyramidal reaction of quetiapine was lese than that of risperidone（χ^2=4.510,P=0.034）.Conclusion：Our study suggested that the treatment efficacy of early schizophrenia in children and adolescence,of quetiapine was the same as that of risperidone,and the extrapyramidal reaction from quetiapine was fewer.